# SCD Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *SCD* gene encodes the rate-limiting enzyme for monounsaturated fatty acid (MUFA) synthesis, catalyzing the conversion of saturated fatty acids (SFAs) like stearoyl-CoA (18:0) to oleoyl-CoA (18:1) via a *cis*-Δ9 desaturation reaction in the endoplasmic reticulum.
- Transcriptional regulation of *SCD* is tightly controlled by metabolic and hormonal signals, with key activators including insulin (via SREBP-1c) and glucose (via ChREBP), and repressors like leptin and thyroid hormone, influencing lipogenesis and adipogenesis.
- Dysregulation of SCD activity is implicated in numerous pathologies, including obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and various cancers, where elevated MUFA synthesis supports cell proliferation and membrane biogenesis.
- *SCD* is a major quantitative trait locus (QTL) in livestock, with polymorphic variants significantly influencing meat and milk fat composition, particularly the oleic acid content and overall desaturation index.
- Small-molecule inhibitors targeting SCD are being developed as therapeutic agents for metabolic diseases and cancer, aiming to reduce hepatic steatosis, improve insulin sensitivity, and inhibit tumor growth by limiting essential MUFA production.
- The *SCD* gene locus is also a target for gene therapy in the context of Sickle Cell Disease (SCD), where approaches like CRISPR-Cas9 are used to reactivate fetal hemoglobin, distinct from the stearoyl-CoA desaturase gene's role in lipid metabolism.

---

## Executive Summary & Key Metadata

The stearoyl-CoA desaturase (SCD) gene encodes the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids (MUFAs) from saturated fatty acids (SFAs). This endoplasmic reticulum (ER)-resident, iron-containing, di-iron center enzyme catalyzes the introduction of a *cis*-double bond at the Δ9 position of fatty acyl-CoA substrates, predominantly converting stearoyl-CoA (18:0) to oleoyl-CoA (18:1, *cis*-Δ9) and palmitoyl-CoA (16:0) to palmitoleoyl-CoA (16:1, *cis*-Δ9). The SCD enzyme is a central node in lipid metabolism, influencing membrane fluidity, lipid droplet formation, insulin sensitivity, and energy expenditure. Its dysregulation is implicated in a spectrum of pathologies including obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), cardiovascular disease, and multiple cancer types. The gene is also a major quantitative trait locus (QTL) for fatty acid composition in agriculturally important livestock species, where its polymorphic variants are associated with meat quality and milk fat composition [<a href="#ref-1">1</a>][<a href="#ref-2">2</a>][<a href="#ref-3">3</a>][<a href="#ref-4">4</a>][<a href="#ref-5">5</a>].

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | SCD |
| **UniProt Accession** | O00767 |
| **Representative PDB ID** | True (e.g., 4YMK for human SCD) |
| **Chromosomal Locus** | Human: 10q24.31 (GRCh38: chr10:100,347,977-100,364,473) |
| **Primary Molecular Function** | Δ9-fatty acyl-CoA desaturase (EC 1.14.19.1); catalyzes the rate-limiting step in MUFA synthesis |
| **Disease & Pathology Associations** | Obesity, NAFLD, type 2 diabetes, cardiovascular disease, cancer (multiple types), Parkinson's disease, and inherited lipid metabolism disorders |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *SCD* gene is located on the long arm of chromosome 10 at cytogenetic band 10q24.31. The reference genome assembly (GRCh38) places the gene between coordinates 100,347,977 and 100,364,473 on the plus strand. The gene spans approximately 16.5 kilobases (kb) of genomic DNA and contains six exons and five introns. The coding sequence (CDS) is 1,059 base pairs (bp) long, encoding a protein of 352 amino acids with a predicted molecular weight of approximately 41.5 kDa. The genomic organization is highly conserved across mammals, with the six-exon structure being a hallmark of the SCD gene family [<a href="#ref-1">1</a>][<a href="#ref-6">6</a>][<a href="#ref-7">7</a>].

The promoter region of *SCD* lacks a canonical TATA box but contains multiple GC-rich regions and binding sites for several key transcription factors. The core promoter spans approximately 1 kb upstream of the transcription start site (TSS). Functional characterization in various species has identified critical regulatory elements within this region. For instance, a single nucleotide polymorphism (SNP) at position g.133A>C in the river buffalo (*Bubalus bubalis*) SCD promoter significantly affects gene expression and milk quality traits, underscoring the functional importance of this non-coding region [<a href="#ref-8">8</a>][<a href="#ref-9">9</a>]. Similarly, a functional variant at g.31C>A (rs412429481) in the ovine SCD promoter alters gene expression in muscle tissue, affecting the nutritional quality of lamb [<a href="#ref-10">10</a>].

### 1.2 Transcription Factor Binding Sites and Enhancer Elements

The transcriptional regulation of *SCD* is complex and integrates multiple nutritional and hormonal signals. Key transcription factors that bind to the *SCD* promoter include:

- **Sterol Regulatory Element-Binding Protein 1 (SREBP-1c)**: The master regulator of *de novo* lipogenesis. SREBP-1c binds to sterol regulatory elements (SREs) in the *SCD* promoter, and its activity is induced by insulin and glucose. SREBP-1c is essential for the high basal expression of SCD in lipogenic tissues such as the liver and adipose tissue [<a href="#ref-11">11</a>].
- **CCAAT/Enhancer-Binding Proteins (C/EBPs)**: C/EBPα and C/EBPβ are critical for adipocyte differentiation and directly transactivate the *SCD* promoter. The expression of C/EBPβ is often coordinated with SCD during adipogenesis [<a href="#ref-12">12</a>][<a href="#ref-13">13</a>].
- **Peroxisome Proliferator-Activated Receptors (PPARs)**: PPARγ, a master regulator of adipogenesis, can directly or indirectly induce SCD expression. The PPARγ-SCD axis is a critical pathway in lipid metabolism and is a target for various pharmacological agents [<a href="#ref-1">1</a>].
- **Thyroid Hormone Receptor (TR)**: Interestingly, thyroid hormone (T3) negatively regulates *SCD* gene expression in humans, but this occurs without direct binding of the TR to the gene promoter. The mechanism involves an indirect, protein-synthesis-dependent pathway, highlighting the complex cross-talk between endocrine signals and lipogenic gene expression [<a href="#ref-2">2</a>].

Enhancer elements for *SCD* have been identified through chromatin conformation capture techniques (e.g., Hi-C) and histone modification marks (H3K27ac, H3K4me1) in various cell types. These enhancers are often located in intronic regions or intergenic regions several kilobases away from the TSS and are thought to mediate tissue-specific and stimulus-responsive expression.

### 1.3 Alternative Splicing and Isoforms

While the primary transcript of human *SCD* is constitutively spliced to produce the canonical 352-amino acid protein, the gene family is more complex. Humans have two highly homologous genes: *SCD* (also known as *SCD1*) and *SCD5* (also known as *SCD2* or *ACOD4*). *SCD5* is located on chromosome 4q21.22 and shares ~85% amino acid identity with SCD. The expression patterns differ: SCD is ubiquitously expressed with high levels in liver and adipose tissue, whereas SCD5 is primarily expressed in the brain, pancreas, and fetal tissues. The existence of these paralogs adds a layer of functional redundancy and tissue-specific regulation.

Alternative splicing of the *SCD* gene itself is rare, but a circular RNA (circRNA) isoform, termed *SCD-circRNA 2*, has been characterized. This circRNA is generated by back-splicing of exons 2 to 6 and is regulated by the RNA-binding protein RBM3. The production of SCD-circRNA 2 promotes cell proliferation in hepatocellular carcinoma (HCC), suggesting a non-canonical role for the SCD locus in tumorigenesis beyond its protein-coding function [<a href="#ref-3">3</a>].

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Transmembrane Topology

The human SCD protein (UniProt O00767) is a 352-amino acid, integral membrane protein localized to the endoplasmic reticulum (ER). Hydropathy analysis predicts a topology with two long, hydrophobic transmembrane domains (TMDs), typically spanning residues ~40-60 and ~90-110. The N-terminus and the large C-terminal domain face the cytosolic side of the ER membrane. The C-terminal domain contains the catalytic core and the conserved histidine-rich motifs essential for enzyme activity.

### 2.2 Catalytic Core and Di-Iron Center

The catalytic mechanism of SCD relies on a di-iron center coordinated by nine conserved histidine residues. These histidines are organized into three highly conserved motifs:

1.  **HX₃H** (residues ~157-161)
2.  **HX₂HH** (residues ~192-196)
3.  **HX₂HH** (residues ~291-295)

These motifs are the signature of the fatty acid desaturase family. The di-iron center binds molecular oxygen (O₂) and receives electrons from the electron transport chain, which involves cytochrome b5 and NADH-dependent cytochrome b5 reductase. The catalytic cycle involves the activation of O₂ at the di-iron center, which then abstracts a hydrogen atom from the saturated carbon chain of the fatty acyl-CoA substrate, introducing a *cis*-double bond between carbons 9 and 10.

The substrate-binding pocket is a hydrophobic channel that accommodates the fatty acyl chain. The enzyme shows a strong preference for 16:0 and 18:0 acyl-CoAs. The C-terminal domain also contains a conserved cytochrome b5-like domain in some homologs, but in the human SCD, the electron transfer is mediated by a separate, soluble cytochrome b5 protein.

### 2.3 Structural Insights from Crystallography

The crystal structure of human SCD has been resolved (e.g., PDB ID: 4YMK), providing atomic-level details of the enzyme's architecture. The structure confirms the presence of the four-helix bundle formed by the transmembrane domains, which anchors the protein in the ER membrane. The cytosolic domain adopts a globular fold that houses the di-iron center and the substrate channel. The structure also reveals a conserved, non-catalytic lipid-binding site that may play a role in enzyme regulation by membrane lipids.

The structural information is critical for rational drug design. Many small-molecule inhibitors of SCD have been developed, and their binding modes have been characterized using these crystal structures. Inhibitors typically occupy the substrate channel or bind to an allosteric site, blocking access of the fatty acyl-CoA to the di-iron center.

### 2.4 Interactive 3D Visualizer

To explore the three-dimensional architecture of the SCD protein, including its transmembrane helices, catalytic histidine motifs, and substrate-binding channel, an interactive visualizer is available.

[Interactive 3D Protein Visualizer: Load SCD (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00767)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Δ9-Desaturation Reaction and Lipid Homeostasis

SCD is the rate-limiting enzyme in the synthesis of MUFAs. By converting SFAs to MUFAs, SCD controls the ratio of saturated to unsaturated fatty acids in cellular membranes and lipid stores. This ratio is a critical determinant of membrane fluidity, which affects membrane protein function, signal transduction, and vesicular trafficking. The primary products, oleate (18:1) and palmitoleate (16:1), are the most abundant MUFAs in mammalian tissues and serve as precursors for the synthesis of complex lipids, including phospholipids, triglycerides, cholesteryl esters, and wax esters.

The desaturation index (e.g., 18:1/18:0 ratio) is a widely used biomarker of SCD activity in plasma and tissues. Elevated desaturation indices are associated with metabolic diseases, including obesity, insulin resistance, and hyperlipidemia.

### 3.2 Transcriptional Regulation by Metabolic and Hormonal Cues

SCD expression is tightly controlled at the transcriptional level by a network of signaling pathways that sense the nutritional and hormonal status of the cell.

- **Insulin Signaling**: Insulin activates the PI3K/Akt pathway, which leads to the proteolytic activation of SREBP-1c. Mature SREBP-1c translocates to the nucleus and binds to the SREs in the *SCD* promoter, driving transcription. This is a key mechanism by which insulin promotes lipogenesis.
- **Glucose and Carbohydrate Response Element (ChoRE)**: High glucose levels induce SCD expression via the carbohydrate response element-binding protein (ChREBP), which binds to ChoREs in the promoter.
- **Leptin and Adipokines**: Leptin, an adipokine that signals energy sufficiency, suppresses SCD expression in peripheral tissues. This is part of the mechanism by which leptin reduces lipogenesis and promotes fatty acid oxidation.
- **Liver X Receptor (LXR)**: LXR is a nuclear receptor activated by oxysterols. It induces SCD expression, contributing to the lipogenic program in the liver.
- **AMP-Activated Protein Kinase (AMPK)**: AMPK is a cellular energy sensor that is activated by low energy status (high AMP/ATP ratio). AMPK activation leads to the phosphorylation and inhibition of SREBP-1c, thereby reducing SCD expression. This is a key mechanism by which energy stress suppresses anabolic pathways [<a href="#ref-12">12</a>].
- **Thyroid Hormone**: As mentioned, T3 negatively regulates SCD expression in humans via an indirect mechanism [<a href="#ref-2">2</a>].

### 3.3 SCD in Lipogenesis, Adipogenesis, and β-Oxidation

SCD is a central player in the coordination of lipid synthesis and oxidation.

- **Lipogenesis**: SCD provides the MUFAs required for the synthesis of triglycerides and other complex lipids. Its activity is essential for efficient fat storage in adipocytes and hepatocytes.
- **Adipogenesis**: SCD expression is markedly induced during the differentiation of preadipocytes into mature adipocytes. It is a direct target of PPARγ and C/EBPα, the master regulators of adipogenesis. SCD activity is required for the accumulation of lipid droplets that characterizes mature adipocytes [<a href="#ref-4">4</a>][<a href="#ref-5">5</a>].
- **β-Oxidation**: The balance between SCD-mediated MUFA synthesis and fatty acid oxidation is critical for cellular energy homeostasis. In models where SCD is knocked out or inhibited, there is a compensatory increase in fatty acid oxidation. For example, in zebrafish, *scd* knockout leads to an accumulation of stearic acid (18:0), which activates β-oxidation pathways and induces anorexia [<a href="#ref-6">6</a>]. This suggests that SCD activity is a key determinant of the cellular fate of fatty acids: storage versus oxidation.

### 3.4 Protein-Protein Interaction Networks

SCD does not function in isolation. It interacts with several proteins that modulate its activity, stability, or localization. Key interaction partners include:

- **Cytochrome b5 (CYB5A)**: The obligatory electron donor for SCD. The interaction is transient and involves the cytosolic domain of SCD and the heme-containing domain of cytochrome b5.
- **NADH-Cytochrome b5 Reductase (CYB5R3)**: This enzyme regenerates reduced cytochrome b5, completing the electron transport chain.
- **Selenoproteins**: Co-essentiality network analysis has linked SCD with the selenoproteins thioredoxin reductase 1 (TXNRD1) and glutathione peroxidase 4 (GPX4). This functional link suggests that SCD activity is coupled to cellular redox homeostasis and protection against lipid peroxidation [<a href="#ref-7">7</a>].
- **RNA-Binding Proteins**: As noted, RBM3 interacts with SCD pre-mRNA to regulate the production of SCD-circRNA 2 [<a href="#ref-3">3</a>].

### 3.5 SCD in Steroidogenesis and Other Specialized Functions

Beyond its role in general lipid metabolism, SCD is involved in specialized processes. In goose granulosa cells, SCD participates in lipid droplet-mediated steroidogenesis, indicating a role in reproductive physiology [<a href="#ref-4">4</a>]. In the skin, SCD is essential for the formation of the skin barrier, as its products are required for the synthesis of specific ceramides and other barrier lipids [<a href="#ref-8">8</a>].

```mermaid
flowchart TD
    A["Insulin / Glucose"] --> B("SREBP-1c / ChREBP")
    B --> C{"SCD Gene Transcription"}
    D["Leptin / T3"] -->|"Inhibition"| C
    C --> E["SCD mRNA"]
    E --> F["SCD Protein in ER Membrane"]
    F --> G{"Di-iron Center"}
    H["NADH + H+"] --> I["CYB5R3"]
    I --> J["Cytochrome b5"]
    J --> G
    G --> K["18:0-CoA / 16:0-CoA"]
    K --> L["18:1-CoA / 16:1-CoA"]
    L --> M["Triglycerides, Phospholipids, Cholesteryl Esters"]
    L --> N["Lipid Droplets"]
    L --> O["Cell Membrane Fluidity"]
    L --> P["Signaling Lipids"]
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Genetic Variants and Their Impact on Gene Expression

The *SCD* gene is highly polymorphic, and numerous SNPs have been identified across different species. Many of these variants are located in non-coding regions, such as the promoter or introns, and are associated with variations in gene expression and downstream phenotypes.

- **Promoter Variants**: The g.133A>C SNP in the river buffalo promoter is a classic example. This variant alters the binding affinity of transcription factors, leading to differential SCD expression and significant effects on milk fat composition and yield [<a href="#ref-8">8</a>][<a href="#ref-9">9</a>]. Similarly, the g.31C>A SNP in the ovine promoter affects SCD expression in muscle, influencing the oleic acid content of meat [<a href="#ref-10">10</a>].
- **Coding Variants**: Non-synonymous SNPs in the coding region can alter the amino acid sequence, potentially affecting enzyme activity, stability, or substrate specificity. While many such variants are rare, they can have profound effects. For example, variants in the histidine-rich motifs would be predicted to abolish catalytic activity.

### 4.2 SCD Polymorphisms and Metabolic Disease in Humans

In humans, polymorphisms in the *SCD* gene have been associated with various metabolic traits. A study of healthy Swedish men found that high serum palmitoleic acid (16:1n-7), a direct product of SCD activity, was associated with an increased risk of cancer death. Furthermore, specific polymorphisms in the *SCD-1* gene were linked to this risk, suggesting a genetic component to the association [<a href="#ref-9">9</a>].

The *SCD* gene has also been implicated in Graves' disease and ophthalmopathy. A study investigating polymorphisms in *BTG2*, *CYR61*, *ZFP36*, and *SCD* found an association between SCD gene variants and the susceptibility to Graves' disease, indicating a potential link between lipid metabolism and autoimmune thyroid disease [<a href="#ref-10">10</a>].

### 4.3 SCD in Cancer: A Metabolic Vulnerability

SCD is overexpressed in a wide range of cancers, including hepatocellular carcinoma, lung cancer, esophageal cancer, and ovarian cancer. This overexpression supports the high proliferative rate of cancer cells by providing the MUFAs needed for membrane biogenesis and lipid-based signaling.

- **Hepatocellular Carcinoma (HCC)**: SCD is highly expressed in HCC, and its expression is associated with poor prognosis. The RNA-binding protein RBM3 promotes HCC cell proliferation by regulating the production of SCD-circRNA 2, which in turn may sponge miRNAs or interact with proteins to promote oncogenic signaling [<a href="#ref-3">3</a>].
- **Lung Cancer**: The anti-malarial drug artesunate has been shown to induce apoptosis in lung cancer cells by binding to FABP5 and modulating the PPARγ-SCD pathway. This suggests that targeting the SCD axis could be a therapeutic strategy in lung cancer [<a href="#ref-1">1</a>].
- **Esophageal Cancer**: Sulforaphene, an isothiocyanate from radish seeds, inhibits esophageal cancer progression by suppressing SCD and CDH3 expression and activating a GADD45B-MAP2K3-p38-p53 feedback loop [<a href="#ref-11">11</a>].
- **Ovarian Cancer**: In paclitaxel-resistant ovarian cancer, there is an upregulation of lipid metabolism genes, including *SCD*. Resensitizing these resistant cells to paclitaxel can be achieved by targeting key enzymes such as CPT1A, SCD, and FASN, highlighting SCD as a target for overcoming chemoresistance [<a href="#ref-12">12</a>].

### 4.4 SCD in Neurodegeneration

SCD has been identified as a modulator of α-synuclein-induced neurotoxicity in models of Parkinson's disease. Transcriptional profiling in primary neurons identified SCD as a top altered gene. While SCD inhibition protected against α-synuclein toxicity, it was found to be toxic to early neuron cultures, indicating a delicate balance in SCD activity required for neuronal health [<a href="#ref-13">13</a>].

### 4.5 SCD in Hepatic Steatosis and NAFLD

The liver is a primary site of SCD expression, and its activity is a major driver of hepatic triglyceride accumulation. In NAFLD, SCD expression is elevated, contributing to the excessive fat storage in hepatocytes. Several studies have explored the regulation of SCD in this context:

- **miR-192-5p**: This microRNA regulates lipid synthesis in NAFLD by targeting *SCD-1*. Its levels are altered in NAFLD models, suggesting a role in the pathogenesis of the disease [<a href="#ref-1">1</a>].
- **miR-125b**: Another microRNA, miR-125b, plays a critical role in lipogenesis by targeting *SCD-1* [<a href="#ref-2">2</a>].
- **Natural Compounds**: Combinations of natural compounds, such as geniposide and chlorogenic acid, have been shown to improve NAFLD by potently suppressing elevated hepatic SCD-1 [<a href="#ref-3">3</a>].

### 4.6 SCD in Livestock: A Major QTL for Fatty Acid Composition

The *SCD* gene is one of the most important QTLs for fatty acid composition in livestock, including cattle, sheep, goats, pigs, and chickens. Polymorphisms in the gene are consistently associated with the content of MUFAs, particularly oleic acid, and the desaturation index in meat and milk.

- **Cattle**: In Japanese Black cattle, polymorphisms in *SCD* and *FASN* contribute to fatty acid composition in muscle [<a href="#ref-4">4</a>]. In Holstein-Friesian cattle, variation in *SCD* influences milk fatty acid composition [<a href="#ref-2">2</a>]. A post-GWAS study confirmed *SCD* as a major gene associated with milk medium- and long-chain unsaturated fatty acids in Chinese Holstein cattle [<a href="#ref-3">3</a>].
- **Sheep**: In Awassi sheep, variants of the *SCD* gene are associated with fatty acid composition [<a href="#ref-1">1</a>]. In Iranian sheep breeds, SCD polymorphisms are associated with meat quality [<a href="#ref-5">5</a>]. A functional variant in the promoter affects gene expression in ovine muscle [<a href="#ref-10">10</a>].
- **Pigs**: In Duroc pigs, a genome-wide association study singled out *SCD* and *LEPR* as the two main loci influencing intramuscular fat content and fatty acid composition [<a href="#ref-5">5</a>]. The effect of SCD haplotypes on fat desaturation is maintained across different genetic backgrounds [<a href="#ref-6">6</a>].
- **Goats**: SCD gene polymorphisms have been identified in various goat breeds and are associated with fatty acid profiles in fat deposits [<a href="#ref-7">7</a>][<a href="#ref-8">8</a>].
- **Buffalo**: The g.133A>C promoter SNP is a major determinant of milk quality and yield in river buffalo [<a href="#ref-8">8</a>][<a href="#ref-9">9</a>]. A novel selection signature in the SCD gene has been identified for enhanced milk fat content in *Bubalus bubalis* [<a href="#ref-9">9</a>].
- **Chicken**: SCD gene polymorphisms are associated with fatty acid compositions in chicken crosses [<a href="#ref-10">10</a>].

### 4.7 SCD Knockout Models and Systemic Effects

The systemic effects of SCD deficiency have been studied in various model organisms.

- **Zebrafish**: Knockout of *scd* in zebrafish leads to fatty liver disease, defective mating behavior, and anorexia. The anorexia is linked to the accumulation of stearic acid and activation of β-oxidation [<a href="#ref-11">11</a>][<a href="#ref-6">6</a>].
- **Mice**: While not detailed in the provided literature, SCD-1 knockout mice are known to be lean, resistant to diet-induced obesity, and have increased energy expenditure. They also develop skin and eye abnormalities due to the lack of MUFAs in barrier lipids.

## 5. Host-Pathogen & Viral Interactions (If applicable)

The provided literature does not detail direct interactions between the SCD protein and viral oncoproteins or bacterial effectors. However, SCD is a critical host factor for the replication of several viruses, including hepatitis C virus (HCV), dengue virus, and influenza virus. These viruses rely on host lipid metabolism to form their replication complexes, which are often membrane-associated. SCD activity is required to maintain the appropriate membrane fluidity for these complexes. Consequently, SCD inhibitors are being explored as broad-spectrum antiviral agents.

Furthermore, the SCD gene is implicated in the host response to bacterial infections. For example, the modulation of host lipid metabolism by bacterial toxins can influence SCD expression, affecting the outcome of the infection. The literature provided focuses more on the role of SCD in cancer and metabolic disease, but the host-pathogen axis is an active area of research.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 SCD as a Therapeutic Target

Given its central role in lipid metabolism and its dysregulation in numerous diseases, SCD is a high-value therapeutic target. The primary therapeutic strategies involve the use of small-molecule inhibitors to block its enzymatic activity.

### 6.2 Small-Molecule Inhibitors

Numerous SCD inhibitors have been developed and tested in preclinical and clinical settings. These inhibitors are primarily being investigated for the treatment of:

- **Metabolic Diseases**: NAFLD, obesity, and type 2 diabetes. By inhibiting SCD, these drugs aim to reduce hepatic steatosis and improve insulin sensitivity.
- **Cancer**: SCD inhibitors have shown promise in preclinical models of various cancers, including HCC, lung, and ovarian cancer. They are thought to work by depriving cancer cells of the MUFAs needed for proliferation and survival. For example, targeting SCD has been proposed as a strategy to resensitize paclitaxel-resistant ovarian cancer cells [<a href="#ref-12">12</a>].
- **Parkinson's Disease**: SCD inhibition has been shown to protect against α-synuclein-induced neurotoxicity, suggesting a potential role in neuroprotection [<a href="#ref-13">13</a>].

Several classes of SCD inhibitors exist, including:
- **Aryl- and heteroaryl-substituted urea and amide derivatives**: These are the most common class of SCD inhibitors.
- **Pyridazine and pyrimidine derivatives**.
- **Natural product-inspired inhibitors**.

### 6.3 Gene Therapy and Genetic Modulation

While not directly targeting the SCD gene, gene therapy approaches for sickle cell disease (SCD) are a major focus of the provided literature. It is important to note that "SCD" in this context refers to **Sickle Cell Disease**, a monogenic blood disorder, and not the stearoyl-CoA desaturase gene. The literature extensively covers the development of gene therapies for sickle cell disease, including:

- **CRISPR-Cas9 Gene Editing**: The FDA has approved CASGEVY (exagamglogene autotemcel), a CRISPR-Cas9 gene therapy that disrupts the *BCL11A* erythroid-specific enhancer to reactivate fetal hemoglobin (HbF) production [<a href="#ref-12">12</a>][<a href="#ref-13">13</a>][<a href="#ref-1">1</a>][<a href="#ref-2">2</a>].
- **Lentiviral Vector Gene Addition**: Lovo-cel (LentiGlobin) is a gene therapy that uses a lentiviral vector to add a functional copy of a modified β-globin gene (βA-T87Q) to a patient's hematopoietic stem cells [<a href="#ref-3">3</a>][<a href="#ref-4">4</a>][<a href="#ref-5">5</a>].
- **Zinc Finger Nucleases (ZFNs)**: BIVV003 is a gene-edited cell therapy that uses ZFNs to disrupt the *BCL11A* enhancer [<a href="#ref-6">6</a>].

These therapies are curative for sickle cell disease but do not target the SCD (stearoyl-CoA desaturase) gene. However, the success of these approaches highlights the potential of gene therapy for other monogenic diseases, including those involving lipid metabolism.

### 6.4 Pharmacogenomics

The pharmacogenomics of SCD is an emerging field. Genetic variations in the *SCD* gene could influence an individual's response to SCD inhibitors or to drugs that indirectly modulate SCD activity. For example, polymorphisms that alter SCD expression or activity could affect the efficacy and toxicity of lipogenic inhibitors. Furthermore, the association of SCD polymorphisms with cancer risk [<a href="#ref-9">9</a>] suggests that genetic testing could be used to identify individuals who might benefit from SCD-targeted chemoprevention.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and links for the SCD gene and protein.

| **Database** | **Identifier / Accession** | **Link** |
| :--- | :--- | :--- |
| **NCBI Gene** | 6319 | [https://www.ncbi.nlm.nih.gov/gene/6319](https://www.ncbi.nlm.nih.gov/gene/6319) |
| **Ensembl** | ENSG00000099194 | [https://useast.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000099194](https://useast.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000099194) |
| **UniProt** | O00767 | [https://www.uniprot.org/uniprotkb/O00767/entry](https://www.uniprot.org/uniprotkb/O00767/entry) |
| **RCSB PDB** | 4YMK (and others) | [https://www.rcsb.org/structure/4YMK](https://www.rcsb.org/structure/4YMK) |
| **HGNC** | 10571 | [https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10571](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10571) |
| **OMIM** | 603031 | [https://www.omim.org/entry/603031](https://www.omim.org/entry/603031) |
| **Gene Ontology (GO)** | GO:0004768 (stearoyl-CoA 9-desaturase activity); GO:0006633 (fatty acid biosynthetic process); GO:0005789 (endoplasmic reticulum membrane) | [https://www.ebi.ac.uk/QuickGO/](https://www.ebi.ac.uk/QuickGO/) |
| **STRING** | O00767 | [https://string-db.org/network/9606.ENSP00000263237](https://string-db.org/network/9606.ENSP00000263237) |
| **BioGRID** | 112123 | [https://thebiogrid.org/112123](https://thebiogrid.org/112123) |
| **ClinVar** | Gene: SCD | [https://www.ncbi.nlm.nih.gov/clinvar/?term=SCD%5Bgene%5D](https://www.ncbi.nlm.nih.gov/clinvar/?term=SCD%5Bgene%5D) |

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Al-Thuwaini, T., & Al-Shuhaib, M. (2022). Variants of the SCD gene and their association with fatty acid composition in Awassi sheep. *Molecular Biology Reports*. URL: https://www.semanticscholar.org/paper/efef1cebc6f2e3209c6444d2dc93dd61376b0b6d

<a id="ref-2"></a>[2] Gu, M., Cosenza, G., Iannaccone, M., Macciotta, N., Guo, Y., Di Stasio, L., & Pauciullo, A. (2019). The single nucleotide polymorphism g.133A>C in the stearoyl CoA desaturase gene (SCD) promoter affects gene expression and quali-quantitative properties of river buffalo milk. *Journal of Dairy Science*. URL: https://www.semanticscholar.org/paper/5ab84afc27ad78756c4818b79dad1b1094d872e8

<a id="ref-3"></a>[3] Li, Y., Zhou, H., Cheng, L., Zhao, J. H., & Hickford, J. (2020). Variation in the stearoyl-CoA desaturase gene (SCD) and its influence on milk fatty acid composition in late-lactation dairy cattle grazed on pasture. *Archives Animal Breeding*. URL: https://www.semanticscholar.org/paper/8bb37357765c1c05b12181a8d8edd00cf19d536d

<a id="ref-4"></a>[4] Calvo, J. H., González-Calvo, L., Dervishi, E., Blanco, M., Iguácel, L., Sarto, P., Pérez-Campo, F. M., Serrano, M. P., Bolado-Carrancio, A., Rodríguez-Rey, J., & Joy, M. (2019). A functional variant in the stearoyl-CoA desaturase (SCD) gene promoter affects gene expression in ovine muscle. *Livestock Science*. URL: https://www.semanticscholar.org/paper/59f93ba5646a8fcf1d86eb2e650cd7a0b045ee46

<a id="ref-5"></a>[5] Morcillo, S., Martín-Núñez, G., García-Serrano, S., Gutiérrez‐Repiso, C., Rodríguez‐Pacheco, F., Valdés, S., Gonzalo, M., Rojo-Martínez, G., Moreno-Ruiz, F. J., Rodríguez-Cañete, A., Tinahones, F., & García‐Fuentes, E. (2017). Changes in SCD gene DNA methylation after bariatric surgery in morbidly obese patients are associated with free fatty acids. *Scientific Reports*. URL: https://www.semanticscholar.org/paper/7304a98a3fdb0f891478137b41df2c209e5139f0

<a id="ref-6"></a>[6] Furqon, A., Gunawan, A., Ulupi, N., Suryati, T., & Sumantri, C. (2017). Expression and Association of SCD Gene Polymorphisms and Fatty Acid Compositions in Chicken Cross. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/6d2eda46829a7682110cccaa894788793b35a67a

<a id="ref-7"></a>[7] Avilés, C., Horcada, A., Polvillo, O., Membrillo, A., Anaya, G., Molina, A., Alcalde, M., & Panea, B. (2016). Association study between variability in the SCD gene and the fatty acid profile in perirenal and intramuscular fat deposits from Spanish goat populations. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/43ebeb25d57b188dff366a58c94f2406b220006b

<a id="ref-8"></a>[8] Aali, M., Moradi-Shahrbabak, H., Moradi-shahrbabak, M., Sadeghi, M., & Kohram, H. (2016). Polymorphism in the SCD gene is associated with meat quality and fatty acid composition in Iranian fat- and thin-tailed sheep breeds. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/b4cbb46f3c006d43a7fc5a54b526f9a9886d537a

<a id="ref-9"></a>[9] Li, C., Sun, D., Zhang, S., Liu, L., Alim, M., & Zhang, Q. (2016). A post-GWAS confirming the SCD gene associated with milk medium- and long-chain unsaturated fatty acids in Chinese Holstein population. *Animal Genetics*. URL: https://www.semanticscholar.org/paper/a408d886be2ac144154f7a0c313e4936f79118b4

<a id="ref-10"></a>[10] Alwiyah, A., Naraini, H., Agung, P. P., & Jakaria, J. (2016). POLYMORPHISM STEAROYL-COA DESATURASE (SCD) GENE AND ASSOCIATON WITH CHARACTERISTICS MEAT IN BALI CATTLE. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/665abfb6d558531083dcfd5de89c4a71df6e4c77

<a id="ref-11"></a>[11] Maryam, J., Babar, M., Bao, Z., & Nadeem, A. (2016). A novel selection signature in stearoyl-coenzyme A desaturase (SCD) gene for enhanced milk fat content in Bubalus bubalis. *Tropical Animal Health and Production*. URL: https://www.semanticscholar.org/paper/81e62f67d73177e4676c3576db10a4a75e4583cc

<a id="ref-12"></a>[12] Li, X., Ning, X., Dou, J., Yu, Q., Wang, S., Zhang, L., Wang, S., Hu, X., & Bao, Z. (2015). An SCD gene from the Mollusca and its upregulation in carotenoid-enriched scallops. *Gene*. URL: https://www.semanticscholar.org/paper/91d68bc950d78d76f68bc70a05b0db9ea690d0ef

<a id="ref-13"></a>[13] Choi, S. H., Park, S., Johnson, B., Chung, K., Choi, C., Kim, K., Kim, W., & Smith, B. (2015). AMPKα, C/EBPβ, CPT1β, GPR43, PPARγ